EIF2AK3 and pancreatic neoplasm: Husain et al. reported that the administration of δ-TT (200 mg/kg × 2/day) decreased pMEK, pERK, and pAkt expression in pancreatic tumors using a transgenic mouse model of pancreatic cancer [124].